LEO Pharma appoints new Executive Vice President of Global Product Supply
Ballerup, Denmark, August 03, 2022 – LEO Pharma A/S announced today the appointment of Sven Hauptmann as its new Executive Vice President of Global Product Supply, effective August 1, 2022.
Sven joins LEO Pharma with more than 25 years of international experience from Roche where he has held numerous leadership positions within supply chain and manufacturing. He comes with a strong track record delivering world-class results e.g., as Site Lead for Roche’s production site in Ireland, Vice President for Small Molecules Manufacturing and most recently as Senior Vice President for Global Drug Product Manufacturing.
Sven holds a Ph.D. in Chemistry from the Technical University in Darmstadt, Germany and an Executive MBA from Northwestern University – Kellogg School of Management.
“I am delighted and proud to welcome Sven to LEO Pharma. I strongly believe he will bring significant value to our business and drive the transformation agenda in our global product supply as we progress on our ambitious strategy toward 2025,” said Christophe Bourdon, President and CEO of LEO Pharma.
“I am thrilled to join LEO Pharma at such exciting times. LEO Pharma has a long and proud history of innovation and I feel strongly about our mission to advance the standard of care for the benefit of people with skin conditions, their families and society,” said Sven Hauptmann.
Sven Hauptmann succeeds Rhonda Duffy who will be leaving LEO Pharma after more than 29 years with the company. It has been Rhonda’s desire to take time off and spend more time with her family. Rhonda has kindly agreed to ensure a smooth handover in the coming months.
“I would like to thank Rhonda Duffy for her loyalty to LEO Pharma, her drive for constant improvements, and her impressive efforts to bring safe and innovative products to patients. Rhonda’s many years with the company is a testament to her passion for making a difference to patients,” said Christophe Bourdon, President and CEO of LEO Pharma.
Sven Hauptmann's LinkedIn profile
Keywords
Contacts
Karen Støvlbæk Frost
KASFR@leo-pharma.com
VP, Corporate Affairs
Tel: +45 3166 1567
Images
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma appoints Marika Murto to lead Global Product Strategy16.12.2025 09:00:00 CET | Pressemeddelelse
Marika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformation Her appointment as SVP of Global Product Strategy will help unlock LEO Pharma’s portfolio potential, driving patient impact and supporting sustainable growth
LEO Pharma submits adolescent label expansion application for Anzupgo® to EMA15.12.2025 09:00:00 CET | Pressemeddelelse
LEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).1 The label expansion submission for adolescent patients demonstrates LEO Pharma's commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.
LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial17.11.2025 09:00:00 CET | Pressemeddelelse
The ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook6.11.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 6 November, 2025 - In the first nine months of 2025, LEO Pharma continued its robust revenue growth, with significantly improved profitability and free cash flow. As expected, growth accelerated in the third quarter, with the global rollout of Anzupgo® gaining further momentum after its September launch in the U.S. The 2025 financial outlook is updated to reflect the addition of Spevigo® to the portfolio, reinforcing LEO Pharma’s commitment to advancing innovation and expanding access to care. Highlights LEO Pharma’s revenue increased by 7% to DKK 10,064 million, and by 8% at constant exchange rates (CER), entirely driven by organic growth. The revenue growth was led by North America (+27% at CER), with Europe (+2% at CER) and Rest of World (+6% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 9% (CER), driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 41% (CER), in ad
LEO Pharma announces NICE recommendation of reimbursement in England and Wales5.11.2025 12:00:00 CET | Pressemeddelelse
The National Institute for Health and Care Excellence (NICE) has recommended the first-and-only topical treatment for adults in the United Kingdom specifically approved for moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 The Technology Appraisal Guidance (TAG) means NHS organisations in England and Wales must now make Anzupgo® ▼(delgocitinib) cream available for healthcare professionals to prescribe. CHE affects around 4.4 million2,3 adults in the UK, with 70% of those with severe forms reporting problems performing everyday activities4, and 58% saying it interferes with their ability to work5.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom